134 related articles for article (PubMed ID: 34645318)
1. Burden of illness and outcomes in second-line large B-cell lymphoma treatment: real-world analysis of Medicare beneficiaries.
Kilgore KM; Mohammadi I; Wong AC; Snider JT; Cheng P; Schroeder A; Patel AR
Future Oncol; 2021 Dec; 17(35):4837-4847. PubMed ID: 34645318
[TBL] [Abstract][Full Text] [Related]
2. Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.
Snider JT; McMorrow D; Song X; Diakun D; Wade SW; Cheng P
Clin Ther; 2022 Apr; 44(4):521-538. PubMed ID: 35241295
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
Future Oncol; 2024 Feb; 20(6):317-328. PubMed ID: 38050764
[TBL] [Abstract][Full Text] [Related]
4. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e181-e190. PubMed ID: 38433043
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
[TBL] [Abstract][Full Text] [Related]
7. Survival among patients with composite and sequential lymphoma between primary mediastinal lymphoma/diffuse large B-cell lymphoma and classical Hodgkin lymphoma: A population-based study.
Tao Y; Chen H; Liu D; Dai X
Leuk Res; 2021 Dec; 111():106669. PubMed ID: 34333276
[TBL] [Abstract][Full Text] [Related]
8. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy.
Danese MD; Griffiths RI; Gleeson ML; Dalvi T; Li J; Mikhael JR; Deeter R; Dreyling M
Leuk Lymphoma; 2017 May; 58(5):1094-1104. PubMed ID: 27659997
[TBL] [Abstract][Full Text] [Related]
9. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
10. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
11. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients.
Huntington S; Keshishian A; McGuire M; Xie L; Baser O
Leuk Lymphoma; 2018 Dec; 59(12):2880-2887. PubMed ID: 29936866
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
13. Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis.
Puckrin R; Stewart DA; Shafey M
Transplant Cell Ther; 2022 Apr; 28(4):218.e1-218.e4. PubMed ID: 35123117
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
[TBL] [Abstract][Full Text] [Related]
15. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab.
Smith SD; Bolwell BJ; Rybicki LA; Kang T; Dean R; Advani A; Thakkar S; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
Bone Marrow Transplant; 2011 Feb; 46(2):262-6. PubMed ID: 20479706
[TBL] [Abstract][Full Text] [Related]
16. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
17. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
18. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs.
Squires P; Puckett J; Ryland KE; Kamal-Bahl S; Raut M; Doshi JA; Huntington SF
Leuk Lymphoma; 2023; 64(11):1752-1770. PubMed ID: 37497877
[TBL] [Abstract][Full Text] [Related]
19. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy.
Tkacz J; Garcia J; Gitlin M; McMorrow D; Snyder S; Bonafede M; Chung KC; Maziarz RT
Leuk Lymphoma; 2020 Jul; 61(7):1601-1609. PubMed ID: 32270727
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]